New Users Sign-up
We value your input.
Please tell us…


Managing the Ulcerative Colitis Patient who is "Resistant" to 5 ASAs
  Didactic Lecture
Ellen J. Scherl, MD
Weill Medical College
Cornell University
Select Speaker

Featured Topic Information

  Program Overview
Symptoms of Crohn's disease often overlap with other diseases. Objective markers of inflammation are important in determining the choice of therapy. There are newer imaging modalities available and potential new disease activity indices for Crohn's disease.

Target Audience
This activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the management of IBD

Educational Objectives
Upon completion of this activity, participants should be better able to:
    • Describe the natural history of ulcerative colitis and its relationship to treatment modalities  
• Discuss the progression of treatment in ulcerative colitis from nonsystemic therapy to aggressive systemic therapy and surgery
• Describe the relative benefits and drawbacks of dose escalation and switching in patients who fail to respond adequately to initial 5-ASA therapy
• Employ strategies for enhancing adherence to therapy for ulcerative colitis
  Physician Disclosure Statement
• Dr. Ellen Scherl has received grants/research support from Abbott, Centocor, Cerimon, Elan, Prometheus, Salix, UCB

• Dr. Ellen Scherl has been a consultant for or participated in the following speaker's bureaus: Abbott, AstraZeneca, Axcan, Berlex, Centocor, Cerimon, Crohn’s & Colitis Foundation of America (CCFA), PDL, Procter and Gamble, Prometheus Laboratories, Questcor Pharmaceuticals, Salix, Shire, Sigma Tau, Solvay, TAP Pharmaceuticals, UCB, PDL, Cerium, Elan Pharmaceuticals

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and Gi Health Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Purdue University College of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release Date: December 31, 2010 Expiration Date: December 31, 2011.
*This program has expired. CME credit is no longer available.

Faculty Disclosure Statement
All faculty participating in continuing education activities sponsored/provided by Purdue University College of Pharmacy are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials. All additional planning committee members, Focus Medical Communications staff and Purdue University College of Pharmacy staff have no relationships to disclose.

© Copyright 2011-2016 IBDcme.TV.
All rights reserved. This site is maintained as an educational resource for US healthcare providers only. Use of
this website is governed by the Gi Health Foundation terms of use and privacy statement.